Investigational drug · Phase 3
OPC-1085EL
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Open Angle Glaucoma or Ocular Hypertension.
Phase 3Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "OPC-1085EL"
First trial start
2022
Sep 27, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OPC-1085EL", any sponsor or status.
Conditions studied
As listed on its trial records.
- Open Angle Glaucoma or Ocular Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "OPC-1085EL" as an intervention, largest first.
- Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02105272 · 237 participants · Start Apr 2014 · Primary completion Mar 2015
Drug: OPC-1085EL ophthalmic solution; Latanoprost ophthalmic solution · For: Glaucoma; Ocular Hypertension
Sites: Kansai Region, Japan
- OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese SubjectsPivotal-lookingCompleted
Otsuka Beijing Research InstituteOtsuka
NCT05583474 · 204 participants · Start Sep 27, 2022 · Primary completion Nov 22, 2024
Drug: OPC-1085EL; 0.005% Latanoprost · For: Open Angle Glaucoma or Ocular Hypertension
Sites: Shanghai, China
- Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02105285 · 193 participants · Start Apr 2014 · Primary completion Jan 2015
Drug: OPC-1085EL ophthalmic solution; Carteolol long-acting ophthalmic solution · For: Glaucoma; Ocular Hypertension
Sites: Kansai Region, Japan
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02108288 · 30 participants · Start Apr 2014 · Primary completion May 2014
Drug: OPC-1085EL ophthalmic solution; Carteolol long-acting ophthalmic solution and 1 more · For: Glaucoma; Ocular Hypertension
Sites: Kansai Region, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
Yamamoto T, Ikegami T, Ishikawa Y, et al. · Am J Ophthalmol 2016
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Otsuka.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.